Literature DB >> 18454393

[Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?].

C Tappeiner1, B Perren, M E Iliev, B E Frueh, D Goldblum.   

Abstract

PURPOSE: The aim of this communication is to report enophthalmos as a possible new adverse effect of topical bimatoprost treatment. PATIENTS AND METHODS: A retrospective case series of five glaucoma patients under long-term topical bimatoprost treatment was evaluated. Documentation with photo and Hertel exophthalmometry was reviewed.
RESULTS: In all five patients a deep lid sulcus, reduced infraocular fat pads and enophthalmos-suspicious Hertel values were found (mean 11.9 mm; SD 2.4). Other aetiologies for enophthalmos were excluded anamnestically and by clinical examination.
CONCLUSION: Bimatoprost may lead to an alteration of the eyelid with deepening of the lid sulcus and may also be responsible for an iatrogenic orbital fat atrophy. A possible mechanism of action might be the induction of apoptosis of orbital fibroblasts with a remodelling of the extracellular matrix. Prospective studies are necessary to confirm this cross-sectional observation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454393     DOI: 10.1055/s-2008-1027362

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  21 in total

1.  Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.

Authors:  Makoto Aihara; Shiroaki Shirato; Rei Sakata
Journal:  Jpn J Ophthalmol       Date:  2011-09-28       Impact factor: 2.447

2.  Effects of prostaglandin F(2α) on adipocyte biology relevant to graves' orbitopathy.

Authors:  Mohd Shazli Draman; Fiona Grennan-Jones; Lei Zhang; Peter N Taylor; Tommy Kyaw Tun; John McDermott; Paul Moriarty; Daniel Morris; Carol Lane; Seamus Sreenan; Colin Dayan; Marian Ludgate
Journal:  Thyroid       Date:  2013-11-04       Impact factor: 6.568

3.  Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome.

Authors:  You Kyung Lee; Y K Lee; Ji Young Lee; J Y Lee; Jung Il Moon; J I Moon; Myoung Hee Park; M H Park
Journal:  Jpn J Ophthalmol       Date:  2014-08-29       Impact factor: 2.447

Review 4.  [Dynamic Scheimpflug Analyzer (Corvis ST) for measurement of corneal biomechanical parameters : A praxis-related overview].

Authors:  R Herber; N Terai; K R Pillunat; F Raiskup; L E Pillunat; E Spörl
Journal:  Ophthalmologe       Date:  2018-08       Impact factor: 1.059

5.  In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.

Authors:  Hee Young Choi; Ji Eun Lee; Ji Woong Lee; Hyun Jun Park; Ji Eun Lee; Jae Ho Jung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-22       Impact factor: 2.671

6.  Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost.

Authors:  Rei Sakata; Shiroaki Shirato; Kazunori Miyata; Makoto Aihara
Journal:  Jpn J Ophthalmol       Date:  2012-12-13       Impact factor: 2.447

7.  Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution.

Authors:  Rei Sakata; Shiroaki Shirato; Kazunori Miyata; Makoto Aihara
Journal:  Jpn J Ophthalmol       Date:  2014-01-07       Impact factor: 2.447

8.  Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution.

Authors:  R Sakata; S Shirato; K Miyata; M Aihara
Journal:  Eye (Lond)       Date:  2014-09-19       Impact factor: 3.775

9.  Bimatoprost in the treatment of eyelash hypotrichosis.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2010-04-26

10.  Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.

Authors:  Takaiko Yoshino; Takeo Fukuchi; Tetsuya Togano; Masaaki Seki; Hiroko Ikegaki; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.